Beijing Biostar Pharmaceuticals secures HKEX approval for conversion of 147.87 million unlisted shares to H-shares

Bulletin Express03-30

Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full circulation listing of 147.87 million unlisted shares. The clearance, granted on 20 March 2026, will allow these shares—previously unlisted and representing 40.6 % of the company’s share capital—to commence trading as H-shares.

Prior to the transaction, Beijing Biostar’s share structure comprised 216.72 million H-shares (59.4 %) and 147.87 million unlisted shares (40.6 %), yielding a total of 364.59 million shares outstanding. Post-conversion, the total share count remains unchanged, but the company’s entire capital will be represented by H-shares, enhancing secondary-market liquidity and broadening investor access.

A total of 20 investors are involved in the conversion. The three largest participants—SDIC (Shanghai) Technology Transfer Venture Capital Fund, Baygen QT Inc., and Beijing Chongde Hongxin Venture Capital Center—will hold 8.10 %, 5.56 % and 4.26 % of the company’s enlarged H-share base, respectively. No individual shareholder will exceed a 10 % stake as a result of the conversion.

The company first disclosed the application on 6 February 2026 following receipt of a filing notice from the China Securities Regulatory Commission. With HKEX approval in place, completion of the conversion and listing is now subject to customary procedural steps.

Investors are advised to exercise caution when dealing in Beijing Biostar Pharmaceuticals’ shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152234673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152234673","market":"hk","top_or_hot":-1,"title":"Beijing Biostar Pharmaceuticals secures HKEX approval for conversion of 147.87 million unlisted shares to H-shares","media":"Bulletin Express","content":"<p>Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full circulation listing of 147.87 million unlisted shares. The clearance, granted on 20 March 2026, will allow these shares—previously unlisted and representing 40.6 % of the company’s share capital—to commence trading as H-shares.</p>\n<p>Prior to the transaction, Beijing Biostar’s share structure comprised 216.72 million H-shares (59.4 %) and 147.87 million unlisted shares (40.6 %), yielding a total of 364.59 million shares outstanding. Post-conversion, the total share count remains unchanged, but the company’s entire capital will be represented by H-shares, enhancing secondary-market liquidity and broadening investor access.</p>\n<p>A total of 20 investors are involved in the conversion. The three largest participants—SDIC (Shanghai) Technology Transfer Venture Capital Fund, Baygen QT Inc., and Beijing Chongde Hongxin Venture Capital Center—will hold 8.10 %, 5.56 % and 4.26 % of the company’s enlarged H-share base, respectively. No individual shareholder will exceed a 10 % stake as a result of the conversion.</p>\n<p>The company first disclosed the application on 6 February 2026 following receipt of a filing notice from the China Securities Regulatory Commission. With HKEX approval in place, completion of the conversion and listing is now subject to customary procedural steps.</p>\n<p>Investors are advised to exercise caution when dealing in Beijing Biostar Pharmaceuticals’ shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Biostar Pharmaceuticals secures HKEX approval for conversion of 147.87 million unlisted shares to H-shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Biostar Pharmaceuticals secures HKEX approval for conversion of 147.87 million unlisted shares to H-shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full circulation listing of 147.87 million unlisted shares. The clearance, granted on 20 March 2026, will allow these shares—previously unlisted and representing 40.6 % of the company’s share capital—to commence trading as H-shares.</p>\n<p>Prior to the transaction, Beijing Biostar’s share structure comprised 216.72 million H-shares (59.4 %) and 147.87 million unlisted shares (40.6 %), yielding a total of 364.59 million shares outstanding. Post-conversion, the total share count remains unchanged, but the company’s entire capital will be represented by H-shares, enhancing secondary-market liquidity and broadening investor access.</p>\n<p>A total of 20 investors are involved in the conversion. The three largest participants—SDIC (Shanghai) Technology Transfer Venture Capital Fund, Baygen QT Inc., and Beijing Chongde Hongxin Venture Capital Center—will hold 8.10 %, 5.56 % and 4.26 % of the company’s enlarged H-share base, respectively. No individual shareholder will exceed a 10 % stake as a result of the conversion.</p>\n<p>The company first disclosed the application on 6 February 2026 following receipt of a filing notice from the China Securities Regulatory Commission. With HKEX approval in place, completion of the conversion and listing is now subject to customary procedural steps.</p>\n<p>Investors are advised to exercise caution when dealing in Beijing Biostar Pharmaceuticals’ shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"华昊中天医药-B","start_time":0,"source_url":"","article_id":"1152234673","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152234673","pubTimestamp":1774881876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"北京映泰药业获港交所批准将1.4787亿股非上市股份转换为H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Hong Kong, 30 March 2026 — Beijing Biostar Pharmaceuticals Co., Ltd. has received approval from the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) for the conversion and full circulation listing of 147.87 million unlisted shares. The clearance, granted on 20 March 2026, will allow these shares—previously unlisted and representing 40.6 % of the company’s share capital—to commence trading as H-shares.\nPrior to the transaction, Beijing Biostar’s share structure comprised 216.72 million H-shares (59.4 %) and 147.87 million unlisted shares (40.6 %), yielding a total of 364.59 million shares outstanding. Post-conversion, the total share count remains unchanged, but the company’s entire capital will be represented by H-shares, enhancing secondary-market liquidity and broadening investor access.\nA total of 20 investors are involved in the conversion. The three largest participants—SDIC (Shanghai) Technology Transfer Venture Capital Fund, Baygen QT Inc., and Beijing Chongde Hongxin Venture Capital Center—will hold 8.10 %, 5.56 % and 4.26 % of the company’s enlarged H-share base, respectively. No individual shareholder will exceed a 10 % stake as a result of the conversion.\nThe company first disclosed the application on 6 February 2026 following receipt of a filing notice from the China Securities Regulatory Commission. With HKEX approval in place, completion of the conversion and listing is now subject to customary procedural steps.\nInvestors are advised to exercise caution when dealing in Beijing Biostar Pharmaceuticals’ shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152234673","isCrawlerRequest":true}